相似文献
1
KCNH2 pharmacogenomics summary.
Pharmacogenet Genomics. 2010 Dec;20(12):775-7. doi: 10.1097/FPC.0b013e3283349e9c.
2
Polymorphisms and atrial fibrillation: sorting the wheat from the chaff.
Eur Heart J. 2008 Apr;29(7):843-5. doi: 10.1093/eurheartj/ehn066. Epub 2008 Feb 28.
3
The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG).
Eur Heart J. 2008 Apr;29(7):907-14. doi: 10.1093/eurheartj/ehm619. Epub 2008 Jan 25.
4
[KCNQ1, KCNH2, KCNE1 and KCNE2 potassium channels gene variants in sudden manhood death syndrome].
Fa Yi Xue Za Zhi. 2012 Oct;28(5):337-41, 346.
5
LQT5 masquerading as LQT2: a dominant negative effect of KCNE1-D85N rare polymorphism on KCNH2 current.
Europace. 2011 Oct;13(10):1478-83. doi: 10.1093/europace/eur184. Epub 2011 Jun 28.
6
Congenital long QT syndrome: a case report of LQT2 and LQT13 in a neonate.
Europace. 2014 Dec;16(12):1807. doi: 10.1093/europace/euu299.
7
The KCNH2 genetic polymorphism (1956, C>T) is a novel biomarker that is associated with CCB and α,β-ADR blocker response in EH patients in China.
PLoS One. 2013 Apr 22;8(4):e61317. doi: 10.1371/journal.pone.0061317. Print 2013.
8
Protective effect of KCNH2 single nucleotide polymorphism K897T in LQTS families and identification of novel KCNQ1 and KCNH2 mutations.
BMC Med Genet. 2008 Sep 23;9:87. doi: 10.1186/1471-2350-9-87.
9
[A novel mutation of the KCNH2 gene in a family with congenital long QT syndrome].
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2010 Feb;27(1):77-80. doi: 10.3760/cma.j.issn.1003-9406.2010.01.017.
10
Gene symbol: KCNH2.
Hum Genet. 2007 Feb;120(6):911.
引用本文的文献
1
Discovering Potential Compounds for Venous Disease Treatment through Virtual Screening and Network Pharmacology Approach.
Molecules. 2023 Dec 5;28(24):7937. doi: 10.3390/molecules28247937.
2
New insights into the genetic predisposition of brucellosis and its effect on the gut and vaginal microbiota in goats.
Sci Rep. 2023 Nov 16;13(1):20086. doi: 10.1038/s41598-023-46997-x.
3
Modulating the voltage sensor of a cardiac potassium channel shows antiarrhythmic effects.
Proc Natl Acad Sci U S A. 2021 May 18;118(20). doi: 10.1073/pnas.2024215118.
4
Pharmacogenomic Biomarkers and Their Applications in Psychiatry.
Genes (Basel). 2020 Nov 30;11(12):1445. doi: 10.3390/genes11121445.
5
Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines.
Pharmacogenomics J. 2017 Mar;17(2):137-145. doi: 10.1038/tpj.2015.93. Epub 2016 Feb 9.
6
Addressing phenoconversion: the Achilles' heel of personalized medicine.
Br J Clin Pharmacol. 2015 Feb;79(2):222-40. doi: 10.1111/bcp.12441.
7
The KCNH2 genetic polymorphism (1956, C>T) is a novel biomarker that is associated with CCB and α,β-ADR blocker response in EH patients in China.
PLoS One. 2013 Apr 22;8(4):e61317. doi: 10.1371/journal.pone.0061317. Print 2013.
8
Dealing with global safety issues : was the response to QT-liability of non-cardiac drugs well coordinated?
Drug Saf. 2013 Mar;36(3):167-82. doi: 10.1007/s40264-013-0016-z.
9
The importance of being profiled: improving drug candidate safety and efficacy using ion channel profiling.
Front Pharmacol. 2011 Dec 13;2:78. doi: 10.3389/fphar.2011.00078. eCollection 2011.
10
Pharmacogenomics and bioinformatics: PharmGKB.
Pharmacogenomics. 2010 Apr;11(4):501-5. doi: 10.2217/pgs.10.15.
本文引用的文献
1
Common variants at ten loci modulate the QT interval duration in the QTSCD Study.
Nat Genet. 2009 Apr;41(4):407-14. doi: 10.1038/ng.362. Epub 2009 Mar 22.
2
Common variants at ten loci influence QT interval duration in the QTGEN Study.
Nat Genet. 2009 Apr;41(4):399-406. doi: 10.1038/ng.364. Epub 2009 Mar 22.
3
Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation.
J Pharmacol Sci. 2008 Dec;108(4):462-71. doi: 10.1254/jphs.08178fp. Epub 2008 Dec 5.
4
Common candidate gene variants are associated with QT interval duration in the general population.
J Intern Med. 2009 Apr;265(4):448-58. doi: 10.1111/j.1365-2796.2008.02026.x. Epub 2009 Oct 25.
5
Molecular determinants of hERG channel block by terfenadine and cisapride.
J Pharmacol Sci. 2008 Nov;108(3):301-7. doi: 10.1254/jphs.08102fp. Epub 2008 Nov 6.
6
The human ERG1 channel polymorphism, K897T, creates a phosphorylation site that inhibits channel activity.
Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14704-8. doi: 10.1073/pnas.0802250105. Epub 2008 Sep 12.
7
Identification of large gene deletions and duplications in KCNQ1 and KCNH2 in patients with long QT syndrome.
Heart Rhythm. 2008 Sep;5(9):1275-81. doi: 10.1016/j.hrthm.2008.05.033. Epub 2008 Jun 4.
8
Drug binding to the inactivated state is necessary but not sufficient for high-affinity binding to human ether-à-go-go-related gene channels.
Mol Pharmacol. 2008 Nov;74(5):1443-52. doi: 10.1124/mol.108.049056. Epub 2008 Aug 13.
9
hERG potassium channels and the structural basis of drug-induced arrhythmias.
Chem Res Toxicol. 2008 May;21(5):1005-10. doi: 10.1021/tx800035b. Epub 2008 May 1.
10
The non-synonymous coding IKr-channel variant KCNH2-K897T is associated with atrial fibrillation: results from a systematic candidate gene-based analysis of KCNH2 (HERG).
Eur Heart J. 2008 Apr;29(7):907-14. doi: 10.1093/eurheartj/ehm619. Epub 2008 Jan 25.
Zotero 插件